Australia's Lumos Diagnostics jumps on sequential jump in qtrly revenue

Lumos Diagnostics Holdings

20/07/2023 04:19

** Shares of Lumos Diagnostics  LDX.AX  rise as much as 7.3%
to A$0.074  
    ** The diagnostics solutions provider posts qtrly revenue of
$3.5 mln, compared with $2 mln in previous qtr
    ** Says major contributor to rev was provision of diagnostic
test development services and contract manufacturing by services
side of business
    ** Adds that FebriDx, its point-of-care test to
differentiate of bacterial and viral respiratory infections, is
expected to receive first U.S. commercial orders by end of 2023 
    ** Stock up 43.8% this year, as of last close
 

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))